Dermatologic composition containing
Disclosed is a composition comprising an effective amount of a mixture of inactivated Escherichia coli and Enterococcus faecalis as well as pharmaceutically acceptable excipients and/or carriers for use in the treatment, supportive treatment or prevention of dermatologic conditions and diseases.
1. A pharmaceutical composition in topically applicable form comprising an effective amount of a mixture of inactivated Escherichia coli and Enterococcus faecalis as well as pharmaceutically acceptable excipients and/or carriers for use in the treatment, supportive treatment or prevention of dermatologic conditions and diseases.
2. The pharmaceutical composition according to claim 1 , wherein Escherichia coli and Enterococcus faecalis are present as a lysate.
3. The pharmaceutical composition according to claim 1 , wherein the mixture of Escherichia coli and Enterococcus faecalis is present in an amount of 1-95 wt %, 20-80 wt %, 40-60 wt % or 45-55 wt % of the total composition.
4. The pharmaceutical composition according to claim 1 , wherein Escherichia coli and Enterococcus faecalis are present in the mixture in a ratio of between 0.5:1.5 and 1.5:0.5, 0.75:1.25 and 1.25:0.75, or 1.15:0.85 and 0.85:1.15 or 1.05:0.95 and 0.95:1.05, optionally wherein Escherichia coli and Enterococcus faecalis are present in respective cell counts of 0.5×10 7 to 10×10 7 ; 1.0×10 7 to 7×10 7 ; or 1.5×10 7 to 4.5×10 7 per 100 g of the total mass.
5. The pharmaceutical composition according to claim 1 , wherein the dermatologic disease and the dermatologic condition are selected from dry skin, transepidermal water loss, inflammatory skin diseases and neurodermatitis.
6. The pharmaceutical composition according to claim 1 , wherein the composition is in the form of an ointment, liquid, emulsion or solution.
7. A cosmetic composition, comprising an effective amount of a mixture of inactivated Escherichia coli and Enterococcus faecalis.
8. The cosmetic composition according to claim 7 , wherein the composition is in topically applicable form.
9. The cosmetic composition according to claim 7 , wherein Escherichia coli and Enterococcus faecalis are in the form of a lysate.
10. The cosmetic composition according to claim 7 , wherein the mixture of Escherichia coli and Enterococcus faecalis is present in an amount of 1-95 wt %; 20-80 wt %; 40-60 wt %; or 45-55 wt % of the total composition.
11. The cosmetic composition according to claim 7 , wherein Escherichia coli and Enterococcus faecalis are present in a ratio of between 0.5:1.5 and 1.5:0.5; 0.75:1.25 and 1.25:0.75; or 1.15:0.85 and 0.85:1.15 or 1.05:0.95 and 0.95:1.05, optionally wherein Escherichia coli and Enterococcus faecalis are present in respective cell counts of 0.5×10 7 to 10×10 7 ; 1.0×10 7 to 7×10 7 ; or 1.5×10 7 to 4.5×10 7 per 100 g of the total mass.
12. The cosmetic composition according to claim 7 , wherein the indication for cosmetic application is selected from dry skin and transepidermal water loss.
13. The cosmetic composition according to claim 7 , wherein the composition is in the form of an ointment, liquid, emulsion, or solution.
14. A method for producing a pharmaceutical composition for use in the treatment, supportive treatment, or prevention of dermatologic conditions and diseases according to claim 1 , which pharmaceutical composition is in topically applicable form, comprising mixing together an effective amount of inactivated Escherichia coli and Enterococcus faecalis and pharmaceutically acceptable excipients or carriers suitable for topical application, to obtain the dermatologically effective pharmaceutical composition.
15. A method for producing a cosmetic composition according to claim 7 , comprising mixing together an effective amount of inactivated Escherichia coli and Enterococcus faecalis and cosmetically acceptable topically applicable excipients or carriers to obtain the dermatologically effective cosmetic composition.
16. A method for treating dry skin, transepidermal water loss, an inflammatory skin disease or neurodermatitis, comprising administering topically to the skin of a subject an effective amount of a pharmaceutical composition according to claim 1 .
17. The pharmaceutical composition according to claim 1 , wherein the composition is in the form of an emulsion.
18. The cosmetic composition according to claim 7 , wherein the composition is in the form of an emulsion.